The need for safer, more effective pain management options has now become urgent, according to award-winning scientist Dr Matt Parker, who has recently been awarded a Short Industry Fellowship from the Royal Society.
Over the next 12 months, Dr Parker and his team at Surrey University, as part of the Fellowship, will work with EptivA Therapeutics, a clinical-stage biotechnology company in Oxford, to research a new personalised medication for those suffering from chronic pain. Existing drug treatments for chronic pain often have limited effectiveness, significantly affecting quality of life. Additionally, these treatments can come with considerable side effects, including the risk of abuse, as seen in the opioid crisis.
EptivA employs a data-driven, personalised approach to pain management. Central to this research partnership is their innovative new Pain Cloud® platform, developed in collaboration with biotech firm Infopoly. This platform uses computer modelling to validate new targets for pain research and, crucially, identify the most suitable patient groups for clinical development.
Read more here